Results 151 to 160 of about 26,612 (257)
Pharmacokinetics and Pharmacodynamics of Prusogliptin (DBPR108), a Once-Daily Dipeptidyl Peptidase-4 Inhibitor, in Patients with Type 2 Diabetes. [PDF]
Liu W +13 more
europepmc +1 more source
Suppression of miR‐145‐5p alleviates DN‐associated renal tissue damage by inhibiting NRF2/SLC7A11‐mediated ferroptosis of RTECs. ABSTRACT Purpose This study aimed to investigate the molecular mechanism by which the miR‐145‐5p/NRF2/SLC7A11 axis regulates ferroptosis‐mediated renal tubular epithelial cell (RTEC) injury in diabetic nephropathy (DN ...
Ganlin Wu +5 more
wiley +1 more source
Dipeptidyl Peptidase-4 Inhibitor-associated Bullous Pemphigoid: Recurrence with Epitope Spreading
Hiroyuki Takama +9 more
doaj +1 more source
Effect of Beta-Cell Function on Glucose Variability When Switching From Insulin Degludec Plus a Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide: Preliminary Results From a Pilot Study. [PDF]
Oe Y +10 more
europepmc +1 more source
Dipeptidyl-Peptidase 4 Inhibitor-Induced Variants of Bullous Pemphigoid: A Case Series of Four Patients. [PDF]
Balighi K +4 more
europepmc +1 more source
Study population, methodology and key findings of the study. ABSTRACT Aims This study aimed to evaluate the clinical efficacy of SD‐ΔRR as a novel methodology for short‐duration heart rate variability (HRV) assessment for the diagnosis of diabetic sensorimotor polyneuropathy (DSPN) in patients with diabetes.
Katsuyoshi Katayama +13 more
wiley +1 more source
The Dipeptidyl Peptidase-4 Inhibitor Saxagliptin as a Candidate Treatment for Disorders of Consciousness: A Deep Learning and Retrospective Clinical Analysis. [PDF]
Toker D +4 more
europepmc +1 more source
This study evaluated serum miRNAs as biomarkers in adult patients with SPIDDM. Serum miRNAs were measured at the time of SPIDDM (probable) diagnosis, and miR‐150‐5p was inversely associated with CPI at the last outpatient visit, suggesting its potential utility for predicting subsequent insulin secretory decline.
Hideyuki Okuma +4 more
wiley +1 more source
The difference between HbA1c and estimated A1c (eA1c) was defined as the GGap. The strong association of high GGap with CGM‐based hypoglycemic indices in type 2 diabetes is evident. The large GGap values, relying solely on HbA1c values during treatment, may increase the risk of hypoglycemia in patients with T2DM.
Satomi Sonoda +13 more
wiley +1 more source
This prespecified subgroup analysis of the BIRDIE study demonstrated that Bifidobacterium bifidum G9‐1 improved stool consistency, bowel movement, and quality of life in patients with type 2 diabetes mellitus, chronic kidney disease, and specifically in age ≥ 65 years, male, and those with eGFR ≥60 mL/min/1.73 m2.
Fuki Ikeda +8 more
wiley +1 more source

